MOLECULAR DOCKING STUDIES ON FLAVONOID COMPOUNDS: AN INSIGHT INTO AROMATASE INHIBITORS
Keywords:
Breast cancer, Estrogen, Aromatase, Aromatase inhibitors, Flavonoid compounds, Docking studiesAbstract
Objective: Aromatase is a key enzyme that plays a crucial role in the synthesis of estrogen and has a major effect in pathogenesis of estrogen‑dependent disease, including breast cancer, endometrial cancer, and endometriosis. The abnormal over expression of aromatase can be inhibited by aromatase inhibitors. The objective of the present study is to evaluate the binding interaction of flavonoid compounds with cytochrome P450 enzyme aromatase, which is involved in the metabolism of estrogens and considered as a powerful target for treatment of estrogen-dependent breast cancers.
Methods: To understand the mechanisms involved in the binding of flavonoid compounds and their interactions with the binding site of aromatase, molecular docking studies were carried using Autodock 4.2.
Results: The docking results revealed that, benzoflavanones showed higher binding affinity compared to other class of compounds. The presence of hydrogen bond interaction and cation–π interaction contributed to their higher binding affinity. The flavonoid compounds with unsubstituted or less substituted rings showed higher binding affinity than those with substituted rings. The hydrogen bonding interactions were predominant in all the classes of compounds considered for the study and were found to be important for inhibition. The docking studies showed that the binding energies mainly depend on aromatic properties like cation–π and π–π interactions. These properties play a key role in determining the biological activity of flavonoid compounds.
Conclusion: The present findings provided valuable information on the binding process of flavonoid compounds to the binding site of aromatase and revealed the structural requirement needed for binding.
Downloads
References
Cristofanilli M, Hortobagyi GN. Molecular targets in breast cancer: current status and future directions. Endocr Relat Cancer 2002;9:249–66.
Latest World Cancer Statistics Global Cancer Burden Rises to 14.1 Million New Cases in: Marked Increase in Breast Cancers must be Addressed. Press release, WHO; 2013. p. 2012.
Suvannang N, Nantasenamat C, Isarankura–Na–Ayudhyaand C, et al. Molecular docking of aromatase inhibitors. Molecules 2011;16:3597–617.
Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Bio 2006;102(1–5):89–96.
Mirzaie S, Chupani L, Asadabadi EB, et al. Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: a computational approach in drug design. EXCLI J 2013;12:168–83.
Benson JR, Ravisekar O. Aromatase inhibitors for the treatment of breast cancer. Curr Canc Ther Rev 2007;3:67–79.
Perez EA. The balance between risks and benefits: long–term use of aromatase inhibitors. EJC Suppl 2006;4:16–25.
Hodek P, Trefil P, Stiborova M. Flavonoids–potent and versatile biologically active compounds interacting with cytochromes p450. Chem Biol Interact 2002;139:1–21.
Chen S, Zhang F, Sherman MA, et al. Structure–Function studies of aromatase and its inhibitors: a progress report. J Steroid Biochem Mol Biol 2003;86:231–7.
Ghosh D, Griswold J, Erman M, et al. Structural basis for androgen specificity and estrogen synthesis in human aromatase. Nat Lett 2009;457:219–24.
Yahiaoui S, Fagnere C, Pouget C, et al. New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem 2008;16:1474–80.
Yahiaoui S, Pouget C, Fagnere C, et al. Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors. Bioorg Med Chem Lett 2004;14:5215–8.
Pouget C, Fagnere C, Basly JP, et al. Design, synthesis and evaluation of 4-imidazolylflavans as new leads for aromatase inhibition. Bioorg Med Chem Lett 2002;12:2859–61.
Pouget C, Fagnere C, Basly JP, et al. New aromatase inhibitors: synthesis and inhibitory activity of pyridinyl-substituted flavanone derivatives. Bioorg Med Chem Lett 2002;12:1059–61.
Murthy JN, Nagaraju M, Sastry GM, et al. Active site acidic residues and structural analysis of modelled human aromatase: a potential drug target for breast cancer. J Comput Aided Mol Des 2006;19:857–70.
Su B, Hackett JC, DÃaz-Cruz ES, et al. Lead Optimization of 7-benzyloxy 2-(4'-pyridylmethyl) thio isoflavone Aromatase Inhibitors. Bioorg Med Chem 2005;13(23):6571–7.
Murthy JN, Nagaraju M, Sastry GM, et al. Active site acidic residues and structural analysis of modelled human aromatase: a potential drug target for breast cancer. J Comput Aided Mol Des 2006;19:857–70.
Morris GM, Goodsell DS, Pique ME, et al. Auto dock4 and AutoDockTools4 automated docking with selective receptor flexibility. J Comput Chem 2009;16:2785–91.
Dewar MJS, Zoebisch EG, Healy EF, Stewart JJP X. AM1: a new general purpose quantum mechanical model. J Am Chem Soc 2003;107:3902–9.
Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639–62.
Laurie AT, Jackson RM. Q-SiteFinder: an energy-based method for the prediction of protein–ligand binding sites. Bioinformatics 2005;21:1908–16.